Sales of Johnson & Johnson's new hepatitis C drug soared during its first full quarter on the market, in another sign of strong demand—and high prices—for a new generation of treatments for the liver-damaging illness.. The higher-than-expected $354 million in first-quarter sales for J&J's Olysio follows evidence that another new hepatitis C drug, Gilead Sciences Inc.'s Sovaldi, is having one of the best-selling drug launches ever. Gilead is scheduled to release results next week; some analysts believe Sovaldi's first-quarter...
  